Measurable residual disease in multiple myeloma: ready for clinical practice?
Leire BurgosNoemi PuigMaria-Teresa CedenaMaría-Victoria MateosJuan José LahuertaBruno PaivaJesús San F MiguelPublished in: Journal of hematology & oncology (2020)
The landscape of multiple myeloma (MM) has changed considerably in the past two decades regarding new treatments, insight into disease biology and innovation in the techniques available to assess measurable residual disease (MRD) as the most accurate method to evaluate treatment efficacy. The sensitivity and standardization achieved by these techniques together with unprecedented rates of complete remission (CR) induced by new regimens, raised enormous interest in MRD as a surrogate biomarker of patients' outcome and endpoint in clinical trials. By contrast, there is reluctance and general lack of consensus on how to use MRD outside clinical trials. Here, we discuss critical aspects related with the implementation of MRD in clinical practice.
Keyphrases
- clinical practice
- clinical trial
- multiple myeloma
- end stage renal disease
- ejection fraction
- newly diagnosed
- healthcare
- chronic kidney disease
- primary care
- prognostic factors
- magnetic resonance
- peritoneal dialysis
- high resolution
- phase ii
- randomized controlled trial
- open label
- quality improvement
- rheumatoid arthritis
- systemic lupus erythematosus
- study protocol
- ulcerative colitis
- mass spectrometry